Podcasts by Not So Different: a Podcast from The Center for Biosimilars
"
Further podcasts by Not So Different: a Podcast from The Center for Biosimilars
Podcast on the topic Gesundheit und Fitness
All episodes
S6 Ep21: Biosimilar Oncology Roundup for November 2023—Podcast Edition from 2023-12-03T12:00
S6 Ep20: Global Biosimilars Week: Dr Fran Gregory Explores the Growing Oncology Biosimilar Space, Previews Future from 2023-11-19T12:00
S6 Ep18: Biosimilars Regulatory Roundup For September 2023– Podcast Edition from 2023-10-02T11:00
S6 Ep16: Biosimilars Business Roundup For August 2023– Podcast Edition from 2023-09-03T11:00
S6 Ep15: How Streamlining Development Can Save the US Biosimilar Industry from 2023-08-20T14:00
S6 Ep14: Biosimilars Immunology Roundup for July 2023- Podcast Edition from 2023-08-06T11:00
S6 Ep13: Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment from 2023-07-16T11:00
S6 Ep12: Biosimilars Business Roundup for June 2023—Podcast Edition from 2023-07-02T11:00
S6 Ep11: Biosimilars Immunology Roundup for May 2023—Podcast Edition from 2023-06-04T11:00
S6 Ep10: What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends from 2023-05-28T11:00
S6 Ep9: Dr. Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings from 2023-05-14T11:00
To read all the articles within the supplement, Listen
S6 Ep7: Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars from 2023-04-16T11:00
To learn more about rheumatologists’ perceptions about RA ... Listen
S6 Ep6: Biosimilars Policy Roundup for March 2023—Podcast Edition from 2023-04-02T11:00
S6 Ep5: How Community Oncologists Can Break Down Biosimilar Adoption Barriers from 2023-03-19T11:00
To listen to our podcast with Cheryl Vaughn, vice president of clinical services at McKesson, discussed how McKesson's Intrafusion service helps manage infusio... Listen
S6 Ep4: Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition from 2023-03-05T12:00
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
Listen
S6 Ep3: On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars from 2023-02-26T12:00
S6 Ep2: Biosimilars Rheumatology Roundup for January 2023—Podcast Edition from 2023-02-05T12:00
S6 Ep1: Seeing Eye to Eye: FDA's Dr Sarah Yim Discusses Efforts to Increase Confidence in Ophthalmology Biosimilars from 2023-01-29T12:00
S5 Ep14: Goodbye 2022—The Top 10 Biosimilars Stories of the Year from 2023-01-01T12:00
S5 Ep13: New Year, New Hurdles: What's in Store for Biosimilars in 2023 from 2022-12-18T12:00
To read more about ophthalmology bios... Listen
S5 Ep12: Biosimilars Regulatory Roundup for November 2022—Podcast Edition from 2022-12-04T12:00
S5 Ep11: What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars from 2022-11-27T12:00
To read more about Amgen’s Biosimilar Trends Report, click Listen
S5 Ep10: AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars? from 2022-11-13T12:00
S5 Ep10: Biosimilars Policy Roundup for October 2022—Podcast Edition from 2022-11-06T12:00
S5 Ep9: Order of Operations: Managing Biosimilars While Maintaining Operational Efficiency from 2022-10-16T11:00
To read more of Kathy’s thoughts on the practice perspective regarding biosimilars, click Listen
S5 Ep8: Biosimilars Oncology Roundup for September 2022—Podcast Edition from 2022-10-02T15:37:32
S5 Ep7: How Heath Policy Can Impact Adoption for Adalimumab Biosimilars from 2022-09-25T11:00
S5 Ep6: What Will Year 1 Look Like for Adalimumab Biosimilars? from 2022-09-11T11:00
S5 Ep5: Biosimilars Regulatory Roundup for August 2022—Podcast Edition from 2022-09-04T11:00
S5 Ep4: Tools of the Trade: How McKesson’s Intrafusion Improves Infusion Center Efficiency, Biosimilar Utilization from 2022-08-21T11:00
S5 Ep3: Not So Different: Biosimilars Oncology Roundup for July 2022—Podcast Edition from 2022-08-07T11:00
S5 Ep2: How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market from 2022-07-24T11:00
S5 Ep1: Dr. Sonia Oskouei Discusses the US Launch of Byooviz, the First Ophthalmology Biosimilar from 2022-07-10T11:00
S4 Ep22: Not So Different: Tactics for Increasing Patient and Provider Confidence in Biosimilars from 2021-10-10T11:00
In the United States, biosimilars can cause some concerns for patients and physicians who may not be fully versed in what biosimilars are. Because biosimilars are not the same as generic drugs, dif...
Listen
S4 Ep21: Not So Different: How 1 Practice is Addressing Biosimilar Concerns Over Savings, Safety, and Efficacy from 2021-10-03T11:00
In the United States, biosimilar uptake has been slow, largely owing to 2 major concerns: that discounts for biosimilars are not substantial enough yet to contribute to significant savings and that...
Listen
S4 Ep20: Not So Different: How Biosimilar Companies Are Stepping Up Their Game to Compete Against Originators from 2021-09-19T11:00
Despite some biosimilars, including those for filgrastim, trastuzumab, and bevacizumab, achieving a greater US market share than their originators, other biosimilar categories, such as pegfilgrasti...
Listen
S4 Ep20: Not So Different: How Biosimilar Companies Are Stepping Up Their Game to Compete Against Originators from 2021-09-19T11:00
Despite some biosimilars, including those for filgrastim, trastuzumab, and bevacizumab, achieving a greater US market share than their originators, other biosimilar categories, such as pegfilgrasti...
Listen
S4 Ep19: Not So Different: Gary Lyman, MD Details What Needs to Be Done to Ensure Physician Confidence in Biosimilars from 2021-08-15T11:00
A major barrier to biosimilar adoption is physician hesitancy when it comes to prescribing these agents, especially in the oncology space. Physicians often want more clinical or real-world evidence...
Listen
S4 Ep19: Not So Different: Gary Lyman, MD Details What Needs to Be Done to Ensure Physician Confidence in Biosimilars from 2021-08-15T11:00
A major barrier to biosimilar adoption is physician hesitancy when it comes to prescribing these agents, especially in the oncology space. Physicians often want more clinical or real-world evidence...
Listen
S4 Ep18: Not So Different: Should Biosimilar Variations Be Concerning? from 2021-08-01T11:00
S4 Ep18: Not So Different: Should Biosimilar Variations Be Concerning? from 2021-08-01T11:00
Although the European Union has been in the biosimilars game longer than the United States, both are considered leaders in biosimilar use. Generics were the first copycat drugs, however, there are ...
Listen
S4 Ep17: Not So Different: What the Generics Industry Can Tell Us About the Future of Biosimilars from 2021-07-18T11:00
On this week’s episode, we sat down with David Senior, senior vice president of Market Economics at AmerisourceBergen. We discussed how the generics market developed in the United States and some o...
Listen
S4 Ep16: Not So Different: Axinn Patent Litigator Discusses Implications of ACA Ruling from 2021-07-04T11:00
S4 Ep16: Not So Different: Axinn Patent Litigator Discusses Implications of ACA Ruling from 2021-07-04T11:00
On June 17, 2021, the Supreme Court ruled that opponents to the Affordable Care Act (ACA) did not have standing to challenge the law based on the constitutionality of the individual mandate, which ...
Listen
S4 Ep15: Not So Different: How Henlius is Making Its Mark on the Global Biosimilar Industry from 2021-06-20T11:00
S4 Ep15: Not So Different: How Henlius is Making Its Mark on the Global Biosimilar Industry from 2021-06-20T11:00
Ping Cao, vice president of Business Development for Shanghai Henlius Biotech, discussed the company's current biosimilar development plans and the process for getting regulatory approval for biosi...
Listen
S4 Ep14: How Pharmacists Can Help Boost Biosimilar Uptake from 2021-05-23T11:00
S4 Ep14: How Pharmacists Can Help Boost Biosimilar Uptake from 2021-05-23T11:00
As the US biosimilar industry continues to expand, physicians, payers, and pharmaceutical companies have been at the forefront of the discussion on how to increase biosimilar uptake and education e...
Listen
S4 Ep13: The Fight to Align Payer Preferences With Community Oncology from 2021-05-09T11:00
In March 2021, the National Comprehensive Cancer Network’s (NCCN) Oncology Research Program, in partnership with Pfizer, announced 10 research projects that will receive funding to develop innovati...
Listen
S4 Ep13: The Fight to Align Payer Preferences With Community Oncology from 2021-05-09T11:00
S4 Ep12: What’s Stopping Physicians From Prescribing Biosimilars? from 2021-04-25T11:00
In March 2021, the National Comprehensive Cancer Network’s (NCCN) Oncology Research Program, in partnership with Pfizer, announced 10 research projects that will receive funding to develop innovati...
Listen
S4 Ep12: What’s Stopping Physicians From Prescribing Biosimilars? from 2021-04-25T11:00
S4 Ep11: How to Improve Perception Hurdles to Biosimilar Adoption from 2021-04-11T11:00
In March 2021, the National Comprehensive Cancer Network’s (NCCN) Oncology Research Program, in partnership with Pfizer, announced that 10 research projects have been chosen to receive funding to f...
Listen
S4 Ep11: How to Improve Perception Hurdles to Biosimilar Adoption from 2021-04-11T11:00
S4 Ep10: Has Brexit Hindered Biosimilar Development? from 2021-04-04T11:00
Maria Manley, LLM, a life sciences expert, talks about how the United Kingdom’s exit from the European Union has changed the regulatory landscape for biologics.
Listen
S4 Ep10: Has Brexit Hindered Biosimilar Development? from 2021-04-04T11:00
S4 Ep9: Dr Juliette Petit: How Nurses Prevent Nocebo Effect in Biosimilar Switching from 2021-03-28T11:00
S4 Ep9: Dr Juliette Petit: How Nurses Prevent Nocebo Effect in Biosimilar Switching from 2021-03-28T11:00
Juliette Petit, MD, a French rheumatologist, talks about her recent study showing that nurses can help curb patient fears and prevent a possible nocebo effect when switching them to a biosimilar.
Listen
S4 Ep8: Minnesota Legislator Discusses Bill to Broaden Biosimilar Coverage from 2021-03-14T11:00
S4 Ep8: Minnesota Legislator Discusses Bill to Broaden Biosimilar Coverage from 2021-03-14T11:00
State Representative Jennifer Schultz (D, Duluth) explains how her bill requiring payers to cover all approved biosimilars and reference products would save money and improve access.
Listen
S4 Ep7: Goodwin Attorneys Discuss Updates to Biosimilars Litigation Guide from 2021-03-07T12:00
S4 Ep7: Goodwin Attorneys Discuss Updates to Biosimilars Litigation Guide from 2021-03-07T12:00
Before the battle for market share gets started, the courtroom is the OK Corral for biosimilar developers and reference product manufacturers, who duke it out over patents to determine how soon bi...
Listen
S4 Ep6: Anar Dossa Discusses Success and Savings With British Columbia’s Biosimilars Initiative from 2021-02-28T12:00
Anar Dossa, director of Pharmacy Services at Pacific Blue Cross, discusses the company projections and challenges that have come with implementing British Columbia's biosimilars initiative.
Listen
S4 Ep5: Sarfaraz Niazi, PhD Discusses Market Projections For High-Concentration Adalimumab Biosimilars from 2021-02-21T12:00
We sat down with Sarfaraz Niazi, PhD, an adjunct professor and biosimilar industry expert, to discuss the potential impact high-concentration adalimumab products could have on the US market.
Listen
S4 Ep4: Steven Lucio Discusses BI’s Citizen Petition and the Current Status of Biosimilars from 2021-02-14T12:00
In late 2020, Boehringer Ingelheim (BI) filed a citizen’s petition requesting the FDA to alter its definition of the word “strength” as used in a section of the Biologics Price Competition and Inno...
Listen
S4 Ep3: The Race to the Top: Does China Have What it Takes? from 2021-02-07T12:00
S4 Ep3: The Race to the Top: Does China Have What it Takes? from 2021-02-07T12:00
China’s regulatory reforms and policy enhancements bode well for a thriving biosimilars industry.
Listen
S4 Ep2: Why You Should Keep Your Eye on Ophthalmology Biosimilars from 2021-01-24T12:00
S4 Ep2: Why You Should Keep Your Eye on Ophthalmology Biosimilars from 2021-01-24T12:00
Recently, one of our Advisory Board members, Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of Biosimilars at Cardinal Health, wrote an opinion piece on the status of ophthalmology medicatio...
Listen
S4 Ep1: Charles Bennett, MD, PhD, Discusses Why the FTC Needs to Join the Effort to Improve the Biosimilar Market from 2021-01-10T12:00
S4 Ep1: Charles Bennett, MD, PhD, Discusses Why the FTC Needs to Join the Effort to Improve the Biosimilar Market from 2021-01-10T12:00
Charles Bennett, MD, PhD, a hematologist and oncologist and professor in the Clinical Pharmacy and Outcomes Sciences Department of the College of Pharmacy at the University of South Carolina, serve...
Listen
S3 Ep32: Sean McGowan on What’s in Store for Biosimilars in 2021 and Beyond from 2020-12-06T12:00
S3 Ep32: Sean McGowan on What’s in Store for Biosimilars in 2021 and Beyond from 2020-12-06T12:00
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, talked about how 2020 has impacted biosimilar development and his predictions for the industry going forward.
Listen
S3 Ep31: A Trio of Experts’ Take on What Needs to Change to Boost Biosimilar Adoption from 2020-11-29T12:00
S3 Ep31: A Trio of Experts’ Take on What Needs to Change to Boost Biosimilar Adoption from 2020-11-29T12:00
The biosimilar market in the United States has had a difficult start since the launch of the first biosimilar in 2015, facing many legal, regulatory, and policy barriers that stall market entry for...
Listen
S3 Ep30: Kathy Oubre On What Practices Can Learn About the Benefits of Implementing Biosimilars from 2020-11-15T12:00
S3 Ep30: Kathy Oubre On What Practices Can Learn About the Benefits of Implementing Biosimilars from 2020-11-15T12:00
On October 28, the Community Oncology Alliance’s (COA) hosted their virtual Payer Exchange Summit on Oncology Payment Reform which featured a panel entitled “Biosimilar Opportunities, Challenges, a...
Listen
S3 Ep29: Steven C. Hill, PhD, Discusses Rebates and Specialty Drug Spending from 2020-11-08T12:00
S3 Ep29: Steven C. Hill, PhD, Discusses Rebates and Specialty Drug Spending from 2020-11-08T12:00
In a recent study, investigators focused on net spending on specialty medicine after manufacturer rebates. What they found was a sharp rise in net specialty drug spending, but they also noted that ...
Listen
S3 Ep28: Nancy Globus, PharmD, on Whether Comparative Efficacy Trials are Necessary from 2020-10-25T11:00
S3 Ep28: Nancy Globus, PharmD, on Whether Comparative Efficacy Trials are Necessary from 2020-10-25T11:00
There has been much debate recently whether comparative clinical efficacy trials are really necessary for demonstrating that a biosimilar candidate is equivalent to a reference product. Many argue ...
Listen
S3 Ep27: Kathy Oubre on What Oncology Practices Lacked During the Pandemic from 2020-10-18T15:22:09
S3 Ep27: Kathy Oubre on What Oncology Practices Lacked During the Pandemic from 2020-10-18T15:22:09
During 7 months of combatting the coronavirus disease 2019 (COVID-19) pandemic, US health care practices, especially in oncology, had to completely modify how they could safely treat patients. They...
Listen
S3 Ep26: Kanika Monga, MD, and Angus Worthing, MD, Discuss ACR Survey on Biosimilars and COVID-19 from 2020-10-11T11:00
S3 Ep26: Kanika Monga, MD, and Angus Worthing, MD, Discuss ACR Survey on Biosimilars and COVID-19 from 2020-10-11T11:00
A recent survey conducted by the American College of Rheumatology (ACR) indicated that a large portion of patients with rheumatic diseases were unsure if they had been prescribed a biosimilar befor...
Listen
S3 Ep25: Wayne Winegarden, PhD, On Why Importing Drugs From Canada Is a Bad Idea from 2020-10-04T11:00
S3 Ep25: Wayne Winegarden, PhD, On Why Importing Drugs From Canada Is a Bad Idea from 2020-10-04T11:00
We sat down with Wayne Winegarden, PhD, a senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI's Center for Medical Economics and Innovation, to discu...
Listen
S3 Ep24: Julie Kennerly-Shah, PharmD, on How Biosimilars Can Help Curb COVID-19's Impact from 2020-09-27T11:00
S3 Ep24: Julie Kennerly-Shah, PharmD, on How Biosimilars Can Help Curb COVID-19's Impact from 2020-09-27T11:00
As summer fades away and the United States prepares for a potential second wave of coronavirus disease 2019 (COVID-19) cases, many are worried that economic impacts and rising health care costs wil...
Listen
S3 Ep23: Rep Grothman on His Bill to Make Biosimilar Insulins Interchangeable from 2020-09-20T11:00
S3 Ep23: Rep Grothman on His Bill to Make Biosimilar Insulins Interchangeable from 2020-09-20T11:00
A major barrier to biosimilar uptake in the United States involves interchangeability, which is a regulatory designation given by the FDA that allows for switches between a reference product and a ...
Listen
S3 Ep22: Alex Moulson on How Companies Choose Which Biosimilars to Produce from 2020-09-13T11:00
S3 Ep22: Alex Moulson on How Companies Choose Which Biosimilars to Produce from 2020-09-13T11:00
Being based in Europe can have unique challenges for a company like Polpharma Biologics, a contract development and manufacturing organization (CDMO) with facilities in Poland and the Netherlands t...
Listen
S3 Ep21: Cheryl Larson on How Employers Can Get Biosimilars Added to Their Health Plan from 2020-09-06T11:00
S3 Ep21: Cheryl Larson on How Employers Can Get Biosimilars Added to Their Health Plan from 2020-09-06T11:00
With the cost of biopharmaceuticals on the rise, employers are looking to biosimilars as a way to cut costs for themselves and their employees now more than ever. However, because the decision-maki...
Listen
S3 Ep20: Jonathan Sweeting on Aybintio's European Approval from 2020-08-30T11:00
S3 Ep20: Jonathan Sweeting on Aybintio's European Approval from 2020-08-30T11:00
In August, Samsung Bioepis, a biopharmaceutical manufacturer based in the Republic of Korea, received European Commission (EC) marketing authorization for its bevacizumab biosimilar, Aybintio.
...
S3 Ep19: Nancy Globus, PharmD, on the Effect of Biosimilar Suffixes from 2020-08-23T11:00
S3 Ep19: Nancy Globus, PharmD, on the Effect of Biosimilar Suffixes from 2020-08-23T11:00
The use of 4-letter suffixes for biologics has been a source of controversy in the United States since the FDA’s guidance on naming was released in 2015. The guidance stated that all newly approved...
Listen
S3 Ep18: Carter Thorne, MD, Discusses Biosimilar Switching in Canada from 2020-08-16T11:00
S3 Ep18: Carter Thorne, MD, Discusses Biosimilar Switching in Canada from 2020-08-16T11:00
We sat down with Carter Thorne, MD, FRCPC, former president of the Canadian Rheumatology Association and chief of the Division of Rheumatology and director of The Arthritis Program at Southlake Reg...
Listen
S3 Ep17: Sizing Up European Biosimilar Competition from 2020-08-09T11:00
S3 Ep17: Sizing Up European Biosimilar Competition from 2020-08-09T11:00
A market’s structure and incentives are critical in ensuring that companies that develop medications like biosimilars have a competitive environment to thrive. Several countries in Europe implement...
Listen
S3 Ep16: Dorothy McCabe, PhD, Discusses How to Combat Biosimilar Misinformation from 2020-08-02T11:00
S3 Ep16: Dorothy McCabe, PhD, Discusses How to Combat Biosimilar Misinformation from 2020-08-02T11:00
We sat down with an author of the opinion piece, Dorothy McCabe, PhD, the executive director of clinical development and medical affairs, immunology and biosimilars at Boehringer Ingelheim Pharmace...
Listen
S3 Ep15: Rathore: What Biosimilar Developers Can Learn From Application Failures from 2020-07-26T11:00
S3 Ep15: Rathore: What Biosimilar Developers Can Learn From Application Failures from 2020-07-26T11:00
Welcome to Not So Different, a podcast from The Center for Biosimilars®. I’m your host, Assistant Editor Skylar Jeremias.
Biologic drug development requires complex processes to obtain des...
S3 Ep14: Byoungseo Choi on Celltrion's Biosimilar Goals For 2030 from 2020-07-19T11:00
You can learn more about the testing of Celltrion's inflixi... Listen
S3 Ep14: Byoungseo Choi on Celltrion's Biosimilar Goals For 2030 from 2020-07-19T11:00
With its infliximab biosimilar, CT-P13 (Inflectra, Remsima) is undergoing trials as a possible treatment for coronavirus disease 2019 (COVID-19), Celltrion Healthcare also has ambitious plans to la...
Listen
S3 Ep13: Ryan Haumschild, PharmD, Discusses Plan to Increase Biosimilar Utilization from 2020-07-12T11:00
S3 Ep13: Ryan Haumschild, PharmD, Discusses Plan to Increase Biosimilar Utilization from 2020-07-12T11:00
We sat down with Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare, to discuss how Emory's biosimilar utilization program has empowered biosimilar utilization within Emory and how E...
Listen
S3 Ep12: Dr Jing Chao Discusses Knowledge Gaps and the Future for Biosimilar Insulins from 2020-07-05T11:00
S3 Ep12: Dr Jing Chao Discusses Knowledge Gaps and the Future for Biosimilar Insulins from 2020-07-05T11:00
Many physicians are wary about prescribing biosimilars, worrying that they are not as safe and effective as their reference products. Additionally, fears could be worsened as there have disturbing...
Listen
S3 Ep11: Joe Fuhr, PhD Discusses His Predictions for the Growing Biosimilar Market from 2020-06-28T11:00
The United States’ slow start to biosimilar uptake has manifested in a number of ways, from delayed launches due to patent disputes to anticompetitive practices creating a distrust of biosimilars a...
Listen
S3 Ep11: Joe Fuhr, PhD Discusses His Predictions for the Growing Biosimilar Market from 2020-06-28T11:00
The United States’ slow start to biosimilar uptake has manifested in a number of ways, from delayed launches due to patent disputes to anticompetitive practices creating a distrust of biosimilars a...
Listen
S3 Ep10: Nick Mitrokostas Discusses New Biosimilar Approval and Outlooks for 2020 from 2020-06-21T11:00
S3 Ep10: Nick Mitrokostas Discusses New Biosimilar Approval and Outlooks for 2020 from 2020-06-21T11:00
Recently, Pfizer announced its pegfilgrastim biosimilar (Nyvepria) was approved by the FDA, which marks the first biosimilar approval this year. Although many expected more approvals earlier in the...
Listen
S3 Ep9: Christine Simmon Discusses AAM Efforts for Biosimilar Legislation from 2020-06-14T14:28
S3 Ep9: Christine Simmon Discusses AAM Efforts for Biosimilar Legislation from 2020-06-14T14:28
Biosimilar manufacturers have to overcome many hurdles in order for their products to be successful in the US market. Some of those hurdles are systemic, such as reimbursement systems that eliminat...
Listen
S3 Ep8: Biosimilar Law Experts Discuss Potential Bills and Chances for Passage from 2020-06-07T11:00
To learn more about all of the bills that were discussed, visit Listen
S3 Ep8: Biosimilar Law Experts Discuss Potential Bills and Chances for Passage from 2020-06-07T11:00
Despite the United States having had a biosimilar pathway for a decade now, the industry has launched just 17 biosimilars on the market, well behind the pace in Europe and India. Several pieces of ...
Listen
S3 Ep7: April Breyer Menon Discusses 2 Potential Bills to Aid Biosimilar Uptake from 2020-05-28T15:40
S3 Ep7: April Breyer Menon Discusses 2 Potential Bills to Aid Biosimilar Uptake from 2020-05-28T15:40
S3 Ep6: Noelle Sunstrom and the Potential Growth for NeuClone from 2020-05-24T11:00
S3 Ep6: Noelle Sunstrom and the Potential Growth for NeuClone from 2020-05-24T11:00
Looking through its robust pipeline of biosimilars, it’s no surprise that Australia based company NeuClone is on its way to become a significant player in the biosimilar industry. To date, the comp...
Listen
S3 Ep5: Dr Sang-Jin Pak Talks Biosimilar Market Stability from 2020-05-03T10:00
Listen
S3 Ep5: Dr Sang-Jin Pak Talks Biosimilar Market Stability from 2020-05-03T10:00
Listen
S3 Ep4: Dr. Sang-Jin Pak Talks Biosimilar Markets: US vs Europe from 2020-04-25T14:23
In April 2020, Samsung Bioepis launched Ontruzant, a biosimilar for trastuzumab, in the US market, in partnership with Merck. The company launched the same drug in Europe in 2018, and it was the fi...
Listen
S3 Ep4: Dr. Sang-Jin Pak Talks Biosimilar Markets: US vs Europe from 2020-04-25T14:23
In April 2020, Samsung Bioepis launched Ontruzant, a biosimilar for trastuzumab, in the US market, in partnership with Merck. The company launched the same drug in Europe in 2018, and it was the fi...
Listen
S3 Ep3:"Not So Different": How the BPCIA Transition Will Impact Biosimilar Uptake from 2020-04-09T20:48
On March 23rd, 2020, the transition under the Biologics Price Competition and Innovation Act was complete, allowing products formerly classified as “small-molecule” drugs, including all insulin pro...
Listen
S3 Ep3: "Not So Different": How the BPCIA Transition Will Impact Biosimilar Uptake from 2020-04-09T20:48
On March 23rd, 2020, the transition under the Biologics Price Competition and Innovation Act was complete, allowing products formerly classified as “small-molecule” drugs, including all insulin pro...
Listen
S3 Ep2: Employers Advocate for Lower Drug Costs Through Biosimilars from 2020-01-13T13:25
S3 Ep2: Employers Advocate for Lower Drug Costs Through Biosimilars from 2020-01-13T13:25
S3 Ep1: Goodwin Attorneys Give a Look at Biosimilar Litigation from 2020-01-05T06:00
S3 Ep1: Goodwin Attorneys Give a Look at Biosimilar Litigation from 2020-01-05T06:00
S2 Ep32: The Year in US Regulatory Activity for Biosimilars from 2019-12-29T06:00
S2 Ep32: The Year in US Regulatory Activity for Biosimilars from 2019-12-29T06:00
Listen
S2 Ep31: At the American College of Rheumatology, a UK Perspective on Biosimilars from 2019-12-22T06:00
S2 Ep31: At the American College of Rheumatology, a UK Perspective on Biosimilars from 2019-12-22T06:00
S2 Ep30: AmerisourceBergen’s Sean McGowan Takes a Closer Look at US Biosimilar Launches from 2019-12-15T06:00
S2 Ep30: AmerisourceBergen’s Sean McGowan Takes a Closer Look at US Biosimilar Launches from 2019-12-15T06:00
S2 Ep29: Celltrion Breaks New Ground With a Subcutaneous Biosimilar Infliximab from 2019-12-08T06:00
S2 Ep29: Celltrion Breaks New Ground With a Subcutaneous Biosimilar Infliximab from 2019-12-08T06:00
S2 Ep28: Biosimilar Business Updates From the Month of November from 2019-12-01T06:00
S2 Ep28: Biosimilar Business Updates From the Month of November from 2019-12-01T06:00
Listen
S2 Ep27: Is There a Role for Biosimilars in Value-Based Models? from 2019-11-24T06:00
S2 Ep27: Is There a Role for Biosimilars in Value-Based Models? from 2019-11-24T06:00
S2 Ep26: HealthyWomen Wants to Educate US Women About Biosimilars from 2019-11-17T06:00
S2 Ep26: HealthyWomen Wants to Educate US Women About Biosimilars from 2019-11-17T06:00
S2 Ep25: AARP Says High Prescription Drug Prices Will Impact All Americans from 2019-11-10T06:00
S2 Ep25: AARP Says High Prescription Drug Prices Will Impact All Americans from 2019-11-10T06:00
S2 Ep24: What's New in Biosimilars in Gastroenterology from 2019-11-03T06:00
S2 Ep24: What's New in Biosimilars in Gastroenterology from 2019-11-03T06:00
S2 Ep23: Strategies for Biosimilar Developers in a Litigious US Landscape from 2019-10-27T05:00
S2 Ep23: Strategies for Biosimilar Developers in a Litigious US Landscape from 2019-10-27T05:00
S2 Ep22: Are We Ready for Biosimilar Rituximab in the United States? from 2019-10-20T05:00
S2 Ep22: Are We Ready for Biosimilar Rituximab in the United States? from 2019-10-20T05:00
S2 Ep21: What Have We Learned So Far About US Oncology Biosimilars? from 2019-10-13T05:00
S2 Ep21: What Have We Learned So Far About US Oncology Biosimilars? from 2019-10-13T05:00
S2 Ep20: OneOncology Gives a Closer Look at Its Biosimilar Adoption from 2019-09-29T05:00
S2 Ep20: OneOncology Gives a Closer Look at Its Biosimilar Adoption from 2019-09-29T05:00
S2 Ep19: Where Are We Headed With Oncology Biosimilars? Vizient Weighs In from 2019-09-15T05:00
S2 Ep19: Where Are We Headed With Oncology Biosimilars? Vizient Weighs In from 2019-09-15T05:00
S2 Ep18: How a Value-Based Pathway Led to Increased Biosimilar Use from 2019-09-01T05:00
S2 Ep18: How a Value-Based Pathway Led to Increased Biosimilar Use from 2019-09-01T05:00
S2 Ep17: What's Next for Drug Pricing After Withdrawal of the Rebate Rule? from 2019-08-18T05:00
S2 Ep17: What's Next for Drug Pricing After Withdrawal of the Rebate Rule? from 2019-08-18T05:00
S2 Ep16: The Biosimilars Council Says Patent Abuses Are Costing Biosimilar Savings from 2019-08-04T05:00
S2 Ep16: The Biosimilars Council Says Patent Abuses Are Costing Biosimilar Savings from 2019-08-04T05:00
S2 Ep15: What Did the First Half of 2019 Hold for Biosimilars? from 2019-07-19T11:44:20
S2 Ep15: What Did the First Half of 2019 Hold for Biosimilars? from 2019-07-19T11:44:20
S2 Ep14: The Biosimilars Forum Wants to Save the Healthcare System Billions from 2019-07-07T05:00
S2 Ep14: The Biosimilars Forum Wants to Save the Healthcare System Billions from 2019-07-07T05:00
S2 Ep13: What's Holding Back Biosimilars? It May Not Be Pay-for-Delay Deals from 2019-06-23T05:00
S2 Ep13: What's Holding Back Biosimilars? It May Not Be Pay-for-Delay Deals from 2019-06-23T05:00
S2 Ep12: A Regulatory Attorney Shares His Take on Interchangeability from 2019-06-09T05:00
S2 Ep12: A Regulatory Attorney Shares His Take on Interchangeability from 2019-06-09T05:00
S2 Ep11: A Look Ahead to Biosimilar Insulin from 2019-05-26T05:00
S2 Ep11: A Look Ahead to Biosimilar Insulin from 2019-05-26T05:00
S2 Ep10: A Look at Biosimilar Education Among European Oncologists from 2019-05-12T05:00
The cost of cancer care is on the rise worldwide, and biosimilars present one option for bringing down costs. However, those savings depend on adoption and use of biosimilars, and hesitancy to u...
Listen
S2 Ep10: A Look at Biosimilar Education Among European Oncologists from 2019-05-12T05:00
The cost of cancer care is on the rise worldwide, and biosimilars present one option for bringing down costs. However, those savings depend on adoption and use of biosimilars, and hesitancy to use ...
Listen
S2 Ep9: Is It Time to Give Up On Biosimilars? from 2019-04-28T05:00
In a 2-part proposal published on the Health Affairs blog, a team of authors argued that efforts to induce lower prices through competition via biosimilars will inevitably fail. Instead, they wr...
Listen
S2 Ep9: Is It Time to Give Up On Biosimilars? from 2019-04-28T05:00
In a 2-part proposal published on the Health Affairs blog, a team of authors argued that efforts to induce lower prices through competition via biosimilars will inevitably fail. Instead, they write...
Listen
S2 Ep8: Drug Pricing in the United States: a Conversation with Robin Feldman from 2019-04-14T03:00
Recent months have seen a variety of proposals to bring down the cost of prescription drugs, but will any of them have staying power? This week, senior editor Allison Inserro speaks with Robin F...
Listen
S2 Ep8: Drug Pricing in the United States: a Conversation with Robin Feldman from 2019-04-14T03:00
Recent months have seen a variety of proposals to bring down the cost of prescription drugs, but will any of them have staying power? This week, senior editor Allison Inserro speaks with Robin Feld...
Listen
S2 Ep7: The Community Oncology Perspective on Drug Pricing Proposals and Biosimilars from 2019-03-31T03:10
The recent weeks and months have seen a number of policy proposals from the Trump administration that impact community oncologists. On this week's podcast, Laura Joszt, associate editorial direc...
Listen
S2 Ep7: The Community Oncology Perspective on Drug Pricing Proposals and Biosimilars from 2019-03-31T03:10
The recent weeks and months have seen a number of policy proposals from the Trump administration that impact community oncologists. On this week's podcast, Laura Joszt, associate editorial director...
Listen
S2 Ep6: Addressing Misinformation on Biosimilars from 2019-03-23T17:00
Last year, biosimilar developer Pfizer submitted a citizen petition to the FDA in which it called on the agency to issue guidance clarifying how drug sponsors can communicate about biosimilars. ...
Listen
S2 Ep6: Addressing Misinformation on Biosimilars from 2019-03-23T17:00
Last year, biosimilar developer Pfizer submitted a citizen petition to the FDA in which it called on the agency to issue guidance clarifying how drug sponsors can communicate about biosimilars. Aft...
Listen
S2 Ep5: Meet the Nonprofit Taking on Generic Drug Shortages from 2019-03-09T18:00
This week on the podcast, we're speaking with Civica Rx’s Heather Wall. She’s the organization’s chief commercial officer, and was recently named one of Modern Heatlhcare’s women leaders to watc...
Listen
S2 Ep5: Meet the Nonprofit Taking on Generic Drug Shortages from 2019-03-09T18:00
This week on the podcast, we're speaking with Civica Rx’s Heather Wall. She’s the organization’s chief commercial officer, and was recently named one of Modern Heatlhcare’s women leaders to watch.
Listen
S2 Ep4:"Not so Different:"The Supreme Court and US Biosimilars from 2019-02-22T11:18:27
Those who follow the biosimilars space closely are aware that, in the context of the US market, legal concerns regarding biosimilars can be just as regulatory ones in informing how drug makers d...
Listen
S2 Ep4: "Not so Different:" The Supreme Court and US Biosimilars from 2019-02-22T11:18:27
Those who follow the biosimilars space closely are aware that, in the context of the US market, legal concerns regarding biosimilars can be just as regulatory ones in informing how drug makers do b...
Listen
S2 Ep3: Where Do We Stand With Provider Education on Biosimilars? from 2019-02-08T14:10:27
Recently, a new systematic review evaluating US and European provider awareness of biosimilars found a persistent lack of education on both sides of the Atlantic. This week, The Center for Biosi...
Listen
S2 Ep3: Where Do We Stand With Provider Education on Biosimilars? from 2019-02-08T14:10:27
Recently, a new systematic review evaluating US and European provider awareness of biosimilars found a persistent lack of education on both sides of the Atlantic. This week, The Center for Biosimil...
Listen
S2 Ep2: How Biosimilars Advanced in 2018 from 2019-01-25T16:03:30
2018 was a banner year for biosimilars, both in the United States and abroad. In this episode of the podcast, Laura Joszt, associate editorial director of The American Journal of Managed Care, i...
Listen
S2 Ep2: How Biosimilars Advanced in 2018 from 2019-01-25T16:03:30
2018 was a banner year for biosimilars, both in the United States and abroad. In this episode of the podcast, Laura Joszt, associate editorial director of The American Journal of Managed Care, inte...
Listen
S2 Ep1: What’s New in Biosimilar Regulation? from 2018-08-17T17:11:35
This season on the podcast, we’re bringing you the news you need to stay up to date on the key issues facing biosimilars. In this episode, we’ll talk about what’s new in biosimilar regulation.
Listen
S2 Ep1: What’s New in Biosimilar Regulation? from 2018-08-17T17:11:35
This season on the podcast, we’re bringing you the news you need to stay up to date on the key issues facing biosimilars. In this episode, we’ll talk about what’s new in biosimilar regulation.
Listen
Episode 10: The Patient Perspective on Biosimilars from 2018-06-03T05:20
Recently, Louis Tharp, the cofounder and executive director of the patient advocacy organization the Global Healthy Living Foundation, visited our studios in New Jersey to talk about how high dr...
Listen
Episode 9: Biosimilars and Expanded Access to Cancer Treatment from 2018-05-20T05:10
Among the great promises of biosimilar therapies is their ability to not only reduce costs for patients and healthcare systems, but to make room in budgets for spending on other high-cost drugs,...
Listen
Episode 8: Medicare and Biosimilars from 2018-05-06T05:00
This week on the podcast, we’re pleased to welcome our guest, Leigh Purvis, MPA. Purvis is the director of health services research at AARP’s public policy institute. Her work focuses on a varie...
Listen
Episode 7: Oncology Biosimilars from 2018-04-22T05:00
This week, we're delving into the world of supportive care and anticancer biosimilars with an oncology expert, Robert M. Rifkin, MD, FACP.
Listen
Episode 6: The Nebraska Rheumatology Society from 2018-04-05T16:00
Today, we're talking about state-level legislation concerning the substitution of interchangeable biosimilars, and how 1 specific piece of biosimilars-focused legislation led to the formation of...
Listen
Episode 5: Policy and Biosimilars from 2018-03-20T19:13:01
Episode 5: Policy and Biosimilars by The Center for Biosimilars
Listen
Episode 4: Creating a Vibrant Biosimilars Market from 2018-03-16T18:42:09
Episode 4: Creating a Vibrant Biosimilars Market by The Center for Biosimilars
Listen
Episode 2: Nonmedical Switching from 2018-02-14T20:33:23
Episode 2: Nonmedical Switching by The Center for Biosimilars
Listen
Episode 1: Interchangeability from 2018-02-02T22:22:27
Episode 1: Interchangeability by The Center for Biosimilars
Listen